Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Vupanorsen (Primary)
- Indications Fatty liver; Hypertriglyceridaemia; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Akcea Therapeutics; Ionis Pharmaceuticals
- 29 Aug 2020 According to an Akcea Therapeutics media release, data from this Phase 2 clinical trial were presented in an online Late Breaking Clinical Trial Session at the ESC Congress 2020, the annual meeting for the European Society of Cardiology.
- 29 Aug 2020 Results presented in an Akcea Therapeutics media release.
- 29 Aug 2020 Results published in the European Heart Journal